Transaction details
Serge Saxonov, CEO of 10x Genomics Inc (NASDAQ: TXG), executed two stock sales on March 2, 2026, disposing of a combined 16,152 shares of Class A common stock. The trades were completed at prices ranging from $22.669 to $23.1781, producing total proceeds of approximately $367,096. The sales were split between 14,292 shares sold at a weighted average price of $22.669 and 1,860 shares sold at a weighted average price of $23.1781.
On the following day, March 3, 2026, Saxonov additionally disposed of 2,750 Class A shares in a transaction that was recorded with a value of $0.
Post-transaction ownership
After these moves, Saxonov directly holds 1,200,917 shares of 10x Genomics common stock. He also has indirect holdings through several trusts: 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust.
Market context and recent company performance
The timing of the CEO’s sales coincided with 10x Genomics shares trading near a 52-week high of $23.56, after the stock gained 105% over the prior 12 months. InvestingPro analysis cited in company reporting indicates the shares appeared slightly undervalued at the time, with a quoted trading price of $22.37.
Earlier reporting for fourth-quarter 2025 showed 10x Genomics outperformed expectations on both earnings and revenue. The company posted an earnings per share (EPS) of -$0.13, versus a consensus forecast of -$0.22. Quarterly revenue was $166 million, beating projections of $157.73 million.
Following the earnings release, two brokerages raised their price targets. Stifel lifted its target to $25 from $20 and maintained a Buy rating, citing strong adoption of the company’s new Flex Apex product as highlighted at the AGBT conference in Florida. Canaccord Genuity also raised its target to $22 from $20 while keeping a Buy rating; that firm’s adjustment followed results that matched the company’s preliminary report earlier in the year. These adjustments were noted as reflecting a favorable competitive position in the single-cell market.
Observation and context limitations
The recorded facts document the scale and timing of the CEO’s sales, the company’s recent operational results, and subsequent analyst revisions. The public record notes a disposal of 2,750 shares valued at $0 on March 3, 2026; the reporting does not provide additional detail about the circumstances or mechanics of that specific entry. Similarly, statements about valuation and competitive positioning are presented as the referenced analysis and analysts’ conclusions rather than definitive measures of future performance.
This article confines itself to the reported transaction figures, ownership levels, quarterly results, and analyst actions as disclosed in company and market reporting.